Diabetes medicines are linked to calmer minds: fewer psychiatric hospital visits for people with schizophrenia

People living with both schizophrenia and type 2 diabetes face a double burden, and their physical-health medicines are rarely studied for mental-health effects. A team led by Najmeh Davoodian analysed US health records for more than 70,000 such adults between 2018 and 2026 and found that those taking GLP-1 medicines (the diabetes drug class now famous for weight loss) were 24% less likely to need psychiatric hospital admission and 29% less likely to need emergency mental-health care than patients on none of the compared medicines. The authors, writing in The Lancet Psychiatry, are careful: records like these can show a link, not prove a cause, and GLP-1s are not a psychiatric treatment. But the signal is strong enough that proper trials now have a clear question to answer.

SDG 3 · Good health and well-being